MedTrace Logo

Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea

NCT00310323 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2009-03-19

No results posted yet for this study

Summary

The purpose of this research study is to determine the effect of chronic nighttime low oxygen saturations on selected body systems (liver) that break down drugs in children with obstructive sleep apnea syndrome (OSAS).

Conditions

Interventions

DRUG

Dextromethorphan

0.5 mg/kg (maximum 30 mg)

DRUG

Caffeine

Administered as 4 ounces of Coca-Cola

Sponsors & Collaborators

  • University of Louisville

    collaborator OTHER

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Mary Jayne Kennedy, Pharm.D. · Virginia Commonwealth University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310323 on ClinicalTrials.gov